Biologicals are moving from the margins of agriculture towards the mainstream. Investment is growing, major companies are expanding their portfolios, regulatory attention is increasing, and more growers and retailers are considering biological products.
Yet an important tension remains:
Market adoption is growing, but consistency, verification, farmer economics, retailer confidence and row-crop scalability remain unresolved.
This discussion is inspired by and acknowledges the AgroPages Media 2026 Biologicals Special. The issue deserves appreciation because it brings together researchers, formulators, manufacturers, regulators, market observers and field practitioners without forcing their different experiences into one simple verdict.
Special appreciation is due to Christina Xie and the AgroPages editorial team for creating space for these perspectives and for encouraging the industry to examine difficult questions openly.
My contribution to the issue, Are Biologicals Becoming What They Were Supposed to Replace?, advances one interpretation: that biological technologies are often being developed, validated, regulated, distributed and commercialised through systems inherited from conventional chemistry. Other contributors and commentators offer complementary or competing interpretations. They point to formulation, manufacturing quality, shelf life, field variability, application compatibility, advisory capacity, economics, communication and integrated pest-management design.
This MetaG1 discussion does not begin with a predetermined answer. It asks one broader but focused question:
What must change for growing biological adoption to become consistent, verifiable, economically sensible and scalable real-world value for farmers?
This is not a discussion about recommending a particular strain, product or application rate. It is also not a contest over isolated yield claims. The concern is the system around the technology: how biologicals are proven, translated into practice, supported after sale, evaluated under real conditions and improved when they fail.
Contributors may wish to consider:
- Is the central constraint product performance, proof, formulation, delivery, regulation, commercial incentives, advisory capability, communication—or an interaction among them?
- Should biologicals be judged as replacements, complements within crop programmes, or steps towards more integrated agroecological systems?
- What evidence should farmers and retailers be able to verify before adoption, and who should be responsible for producing and checking it?
- How should responsibility be shared when a promising product performs inconsistently after leaving the factory?
- Which existing approaches are already working, and should be strengthened rather than replaced?
- What is one practical change that manufacturers, researchers, regulators, distributors, advisers, investors or farmer organisations could begin together?
Supporting and opposing positions are equally welcome. Please distinguish evidence from inference, state the crop and geography behind field experience, disclose relevant commercial interests, and identify what evidence could change your present view.
Intended outcome
The purpose is not to accumulate comments or declare a quick consensus. After sufficient participation, the discussion will be synthesised into:
- points of genuine convergence;
- important disagreements and the evidence behind them;
- claims that remain insufficiently tested;
- practical actions that responsible participants can take; and
- any collaboration, experiment, evidence standard or policy proposal that contributors are willing to carry forward.
A reasoned conclusion that further evidence is required—or that no common action is yet justified—will also be a valid outcome.
If you work with biologicals as a farmer, scientist, product developer, formulator, manufacturer, regulator, retailer, adviser, investor or independent critic, your experience can help move this conversation from expressed opinion towards actionable understanding.